

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Fujian Haixi Pharmaceuticals Co., Ltd.
福建海西新藥創制股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2637)

APPOINTMENT OF SENIOR MANAGEMENT

The board of directors (the “**Board**”) of Fujian Haixi Pharmaceuticals Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dr. Zhang Mingqiang (張明強) (“**Dr. Zhang**”) has been appointed as the President of Research & Development and Global Affairs of the Group with effect from 1 March 2026.

The biographical details of Dr. Zhang are set out below:

Dr. Zhang, aged 65, had extensive experience in pharmaceutical and biotechnology industries. From 1997 to 2001, Dr. Zhang served as the head of medicinal chemistry section of Organon research laboratories (now part of Merck Sharp & Dohme) in Glasgow, the United Kingdom. Before joining the multinational pharmaceutical companies, Dr. Zhang co-founded several biotechnology companies. From 2003 to 2009, Dr. Zhang served as the senior vice president of research & development in Biotica Technology Ltd, Cambridge, UK where he led the research & development activities related to synthetic biology. From 2009 to 2011, Dr. Zhang worked as the chief technology officer and vice president of external research & development at F. Hoffmann-La Roche’s R&D Centre in China. After that, Dr. Zhang (re-)joined Merck Sharp & Dohme and served as corporate vice president and head of Asia Pacific Research & Development from 2011 to 2012. Since 2012 and prior to joining the Group, Dr. Zhang served as corporate vice president of R&D and the head of Asia Research & Development Center of Amgen Inc.

Dr. Zhang received his doctoral degree from the University of Antwerp in Belgium and obtained his post-doctoral training from the Vrije University Amsterdam in the Netherlands.

The Board would like to take this opportunity to express its warmest welcome to Dr. Zhang for joining the Group. Dr. Zhang will provide a critical role in leading business development activities worldwide as well as research and development of novel drugs. The Board is confident that Dr. Zhang's comprehensive experience and in-depth industry knowledge will guide the Group towards achieving its new milestones. His appointment aligns with our strategic goals and is expected to significantly benefit our development. Looking forward, the Group is poised to embrace future opportunities and challenges.

By Order of the Board
Fujian Haixi Pharmaceuticals Co., Ltd.
Dr. Kang Xinshan
Chairman and Executive Director

Fujian, the PRC, 1 March 2026

As at the date of this announcement, the executive Directors are Dr. Kang Xinshan, Ms. Feng Yan, Dr. Chen Guangming and Dr. Chen Shuyi; the non-executive Directors are Mr. Xu Dong and Mr. Wang Xinkun; and the independent non-executive Directors are Mr. Gong Weimin, Ms. Wang Shan Shan and Ms. Pu Meiting.